BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
186 hedge funds and large institutions have $182M invested in bluebird bio in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 63 increasing their positions, 39 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
3% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $5.25M
33% less capital invested
Capital invested by funds: $272M → $182M (-$90.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
186
Holding in Top 10
–
Calls
$5.42M
Puts
$5.25M
Top Buyers
| 1 | +$9.54M | |
| 2 | +$5.46M | |
| 3 | +$4.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.36M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$4.35M |
Top Sellers
| 1 | -$7.6M | |
| 2 | -$5.52M | |
| 3 | -$3.56M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.08M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.37M |